PT 2977

Drug Profile

PT 2977

Alternative Names: PT-2977

Latest Information Update: 15 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Peloton Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Pulmonary arterial hypertension
  • Research Iron overload

Most Recent Events

  • 09 Dec 2016 Phase-I clinical trials in Solid tumours (Metastatic disease) in USA (PO) (NCT02974738)
  • 25 Nov 2016 Early research in Iron overload in USA before November 2016 (PO)
  • 25 Nov 2016 Preclinical trials in Pulmonary arterial hypertension in USA before November 2016 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top